Affiliation:
1. Clinical Pharmacology and Bioanalytics Pfizer Worldwide Research Development and Medical Groton CT USA
2. Global Biometrics and Data Management Pfizer Global Product Development Cambridge UK
3. Early Clinical Development Clinical Sciences Pfizer Worldwide Research, Development and Medical Cambridge MA USA
4. Internal Medicine Research Unit Pfizer Worldwide Research, Development and Medical Cambridge MA USA
Abstract
AbstractDanuglipron (PF‐06882961) is an oral, small‐molecule glucagon‐like peptide‐1 receptor agonist in development for the treatment of type 2 diabetes (T2D) and obesity. Impaired renal function is prevalent in patients with T2D. This Phase 1, open‐label study evaluated the effect of renal impairment on the pharmacokinetics, safety, and tolerability of danuglipron (20 mg) in healthy participants with normal renal function (estimated glomerular filtration rate [eGFR] unnormalized for body surface area: ≥90 mL/min), in participants with T2D and normal renal function (eGFR ≥90 mL/min), and in participants with T2D and mild (eGFR 60‐89 mL/min), moderate (eGFR 30‐59 mL/min), or severe (eGFR <30 mL/min) renal impairment (N = 39). Log‐linear regression analyses and analyses of variance showed no evidence of a clinically significant effect of reduced renal function on danuglipron pharmacokinetics. Renal clearance of unchanged danuglipron was minimal (<1% across all renal function groups). Danuglipron pharmacokinetics were similar between healthy participants and participants with T2D and normal renal function. A single 20‐mg oral dose of danuglipron was generally safe and well tolerated in all participant groups. In participants with T2D, renal impairment had no clinically meaningful effect on the pharmacokinetic, safety, and tolerability profiles of danuglipron, indicating that dose adjustment of danuglipron will not be required when administered to patients with T2D and reduced renal function.
Subject
Pharmacology (medical),Pharmacology
Reference31 articles.
1. International Diabetes Federation. IDF Diabetes Atlas—10th Edition 2021. Accessed April 17 2023.https://diabetesatlas.org/data/en/
2. World Health Organization. Global Report on Diabetes 2016. Accessed April 17 2023.https://www.who.int/publications/i/item/9789241565257
3. Chronic kidney disease and risk management: standards of care in diabetes—2023;American Diabetes Association;Diabetes Care,2023
4. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis
5. Targeted literature review of the burden of illness in patients with chronic kidney disease and type 2 diabetes;Fried LF;Am J Manag Care,2021
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献